Mots-C
Mitochondrial open reading frame of the 12S rRNA-c, MT-RNR1, Mitochondrial-derived peptide MOTS-c
Expression Patterns of MOTS-c in Adrenal Tumors: Results from a Preliminary Study.
Kamiński. Kacper K; Blatkiewicz. Małgorzata M; Szyszka. Marta M; Olechnowicz. Anna A; Komarowska. Hanna H; Klimont. Anna A; Wierzbicki. Tomasz T; Karczewski. Marek M; Ruchała. Marek M; Rucinski. Marcin M
Key Findings
- MOTS‑c mRNA is reduced in adrenal tumors (ACC, ACA, PCC) compared to normal adrenal tissue.
- Serum MOTS‑c protein is higher in benign adenoma (ACA) and pheochromocytoma (PCC) but unchanged in aggressive carcinoma (ACC).
- Within tumor tissue, MOTS‑c protein staining is lower in all tumors and declines further in later stages of ACC.
- Serum MOTS‑c levels positively correlate with glucose, total cholesterol, HDL, LDL, and SHBG, while tumor size and testosterone correlate positively with MOTS‑c mRNA but negatively with serum protein.
Practical Outcomes
- For most biohackers, the study offers little direct guidance on using MOTS‑c as a supplement or therapy, since it only describes how the peptide behaves in disease states. It suggests that altered MOTS‑c levels are linked to metabolic markers, but no dosing, safety, or performance protocols can be derived from these findings.
Summary
Researchers looked at the levels of a tiny protein called MOTS‑c in different adrenal gland tumors and compared them to healthy tissue. They found that the gene that makes MOTS‑c is less active in all tumor types, while the amount of MOTS‑c floating in the blood goes up in some benign tumors but not in the aggressive cancer. The pattern of MOTS‑c in the tumor itself drops as the cancer gets worse, and its blood levels are linked to things like blood sugar and cholesterol.
Abstract
Adrenal tumors, such as adrenocortical carcinoma (ACC), adrenocortical adenoma (ACA), and pheochromocytoma (PCC) are complex diseases with unclear causes and treatments. Mitochondria and mitochondrial-derived peptides (MDPs) are crucial for cancer cell survival. The primary aim of this study was to analyze samples from different adrenal diseases, adrenocortical carcinoma, adrenocortical adenoma, and pheochromocytoma, and compare them with normal adrenal tissue to determine whether the expression levels of the mitochondrial open reading frame of the 12S rRNA type-c (MOTS-c) gene and protein vary between different types of adrenal tumors compared to healthy controls using qPCR, ELISA, and IHC methods. Results showed decreased <i>MOTS-c</i> mRNA expression in all adrenal tumors compared to controls, while serum MOTS-c protein levels increased in ACA and PCC but not in ACC. The local distribution of MOTS-c protein in adrenal tissue was reduced in all tumors. Notably, MOTS-c protein expression declined with ACC progression (stages III and IV) but was unrelated to patient age or sex. Tumor size and testosterone levels positively correlated with <i>MOTS-c</i> mRNA but negatively with serum MOTS-c protein. Additionally, serum MOTS-c protein correlated positively with glucose, total cholesterol, HDL, LDL, and SHGB levels. These findings suggest disrupted expression of <i>MOTS-c</i> in the spectrum of adrenal diseases, which might be caused by mechanisms involving increased mitochondrial dysfunction and structural changes in the tissue associated with disease progression. This study provides a detailed examination of MOTS-c mRNA and protein in adrenal tumors, indicating the potential role of MDPs in tumor biology and progression.
Study Information
pubmed
2024
2024-08-09T00:00:00.000Z
10.3390/ijms25168721
2
64